Seneca Biopharma Inc fka SNCA

[Japes1]

Actually they had 15 patients of varying forms and conditions of ALS. On another blog it was said, if true, they had patients with FALS. A particularly virulent ALS. They tested, it seems, patients they knew were responders in Phase 1, with a diverse group to see who the right candidates might be. In the group of 7 responders, it looks to me, that 100% of those with the "perfect conditions" for the treatment benefitted. The 47% is the number of the percentage of total participants. The trial was mainly for safety. That fact that there was benefit, is amazing. There are FDA approved cancer drugs for terminal patients that only ever showed 30+ percent efficacy. Anyway, just my 5 cents worth.